BIONET Corp. (TPEX:1784)

Market Cap	5.21B
Revenue (ttm)	1.22B
Net Income (ttm)	69.82M
Shares Out	50.31M
EPS (ttm)	1.38
PE Ratio	74.96
Forward PE	n/a
Dividend	1.42 (1.37%)
Ex-Dividend Date	Oct 3, 2025

Volume	412,929
Average Volume	776,417
Open	105.00
Previous Close	105.00
Day's Range	103.00 - 106.00
52-Week Range	62.40 - 117.00
Beta	0.53
RSI	51.78
Earnings Date	Mar 17, 2026

About BIONET

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.